Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for serious autoimmune diseases.
Kyverna Therapeutics is developing an innovative new class of T cell-based therapies and cures for serious autoimmune diseases.
Kyverna Therapeutics was founded in 2018 by Dominic Borie and Jeffrey Greve. The company is headquartered in Berkeley, California.
Kyverna Therapeutics' therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of disease.
Kyverna Therapeutics is backed by Vida Ventures, Westlake Village BioPartners, Gilead Sciences and others. The company raised $25M in a Series A financing on Jan 13, 2020.